External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews

Medical Care

Volumn 44, Issue 2, 2006, Pages 124-131

  Du, Xianglin L ^a   Key, Charles R ^b   Dickie, Lois ^b   Darling, Ronald ^b   Geraci, Jane M ^c   Zhang, Dong ^d  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Breast cancer; Chemotherapy; Medical chart review; Medicare claims; Validity

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; INFORMATION PROCESSING; MEDICAL RECORD; MEDICARE; METHODOLOGY; STATISTICS; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DATA COLLECTION; FEMALE; HUMANS; MEDICAL RECORDS; MEDICARE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);

EID: 33644838449     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000196978.34283.a6     Document Type: Article

References (51)

1. Whittle J, Steinberg EP, Anderson GF, et al. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans. Med Care. 1991;29:1226-1236.
2. Fleming C, Fisher ES, Chang CH, et al. Studying outcomes and hospital utilization in the elderly. The advantages of a merged data base for Medicare and Veterans Affairs hospitals. Med Care. 1992;30:377-391.
3. Nattinger AB, Gottlieb MS, Veum J, et al. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992;326:1102-1107.
4. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
5. Lauderdale DS, Furner SE, Miles TP, et al. Epidemiologic uses of Medicare data. Epidemiol Rev. 1993;15:319-327.
6. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care. 1994:32(Suppl):JS38-JS51.
7. McBean AM, Warren JL, Babish JD. Measuring the incidence of cancer in elderly Americans using Medicare claims data. Cancer. 1994;73:2417-2425.
8. Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716-726.
9. McClish DK, Penberthy L, Whittemore M, et al. Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. Am J Epidemiol. 1997;145:227-233.
10. Du XL, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 1999;52:463-470.
11. Warren JL, Riley GF, Potosky AL, et al. Trends and outcomes of outpatient mastectomy in elderly women. J Natl Cancer Inst. 1998;90:833-840.
12. Iezzoni LI. Data sources and implications: administrative databases. In: Iezzoni LI, ed. Risk Adjustment for Measuring Healthcare Outcomes. Chicago: Health Administration Press; 1997:169-242.
13. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002:40(8 Suppl):49-54.
14. Cooper GS, Yuan Z, Stange KC, et al. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care. 2000;38:411-421.
15. Potosky AL, Warren JL, Riedel ER, et al. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002;40(8 Suppl):62-68.
16. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002:40(8 Suppl):3-18.
17. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(Suppl):IV-55-IV-61.
18. Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461.
19. Du XL, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 2001;92:730-737.
20. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117:1239-1246.
21. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064-1070.
22. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857.
23. Schrag D, Gelfand SE, Bach PB, et al. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results-Medicare. J Clin Oncol. 2001;19:3712-3718.
24. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001;7:213-218.
25. Lamont EB, Lauderdale DS, Schilsky RL, et al. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002;40:201-211.
26. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999-4005.
27. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20:1786-1792.
28. Sundararajan V, Hershman D, Grann VR, et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173-178.
29. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136:349-357.
30. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643-2650.
31. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20:3992-3998.
32. Delea TE, Vera-Llonch M, Edelsberg JS, et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health. 2002;5:35-43.
33. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636-4642.
34. Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-97.
35. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003. Available at: http://seer.cancer.gov/csr/1975_2000. Accessed November 23, 2005.
36. National Cancer Institute. The SEER Program Code Manual. Revised ed. NIH Publication No. 94-1999. Bethesda, MD: National Cancer Institute; 1994.
37. The New Mexico Tumor Registry. About the New Mexico Tumor Registry. Available at: http://hsc.unm.edu/epiccpro/nmtr.html. Accessed November 23, 2005.
38. Hintze J. PASS 2000. Kaysville, Utah: NCSS; 2000.
39. U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Los Angeles: PMIC; 1996.
40. American Medical Association. Physicians' Current Procedural Terminology-CPT 2000. Chicago: American Medical Association; 2000.
41. Health Care Financing Administration. HCFA Common Procedure Coding System (HCPCS): National Level II Medicare Codes. Los Angeles: Practice Management Information Corporation; 2000.
42. Health Care Financing Administration. HCFA Data Dictionary: Revenue Center Codes. June 17, 1999.
43. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. Cary, NC: SAS Institute Inc.; 1997.
44. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580-1584.
45. Hillner BE, McDonald MK, Penberthy L, et al. Measuring standards of care for early breast cancer in an insured population. J Clin Oncol. 1997;15:1401-1408.
46. Siminoff LA, Zhang A, Saunders Sturm CM, et al. Referral of breast cancer patients to medical oncologists after initial surgical management. Med Care. 2000;38:696-704.
47. Keating NL, Landrum MB, Ayanian JZ, et al. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol. 2003;21:4532-4539.
48. Baldwin LM, Taplin SH, Friedman H, et al. Access to multidisciplinary cancer care: is it linked to the use of breast-conserving surgery with radiation for early-stage breast carcinoma? Cancer. 2004;100:701-709.
49. Iezzoni LI. Data Sources and Implications: Information from Medical Records and Patients. In Iezzoni LI, ed. Risk Adjustment for Measuring Healthcare Outcomes. Chicago, IL: Health Administration Press; 1997: 243-278.
50. Feinstein AR. Principles of Medical Statistics. Boca Raton, FL: Chapman & Hall/CRC; 2002:415-418.
51. Du XL, Freeman JL, Warren JL, et al. Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer. Med Care. 2000;38:719-727.